AYTU vs PATH · rev $66.4M vs P/E 19, rev $1.61B
Aytu BioScience Inc (AYTU) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Aytu BioScience Inc (AYTU) is a drug manufacturers - specialty & generic company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported AYTU revenue for 2025-06-30 was $66.4M. Net income was -$13.6M. Revenue was up 1.8% from 2024-06-30 to 2025-06-30. AYTU currently screens at market cap $24.1M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
AYTU currently screens at market cap $24.1M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the AYTU and PATH stock pages for the full models.
Not investment advice.